Crewe Advisors’s Spero Therapeutics SPRO Stock Holding History

Crewe Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-258	Closed	-$1K	–	1244
2022 Q3	$1K	Buy	+258	New	+$257	﹤0.01%	1200

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Crewe Advisors's SPRO Position: Q4 2022 in Review

Crewe Advisors sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 258 shares — an estimated $1K sold.

Crewe Advisors first reported a position in SPRO in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

Crewe Advisors reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 258 Spero Therapeutics shares in Q4 2022, an estimated $1K.
Crewe Advisors first reported a position in Spero Therapeutics in Q3 2022 and held it in 1 quarter.
Crewe Advisors's Spero Therapeutics position peaked at $1K in Q3 2022.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.